ルセオグリフロジン水和物 化学特性,用途語,生産方法
効能
糖尿病治療薬, SGLT-2阻害薬
商品名
ルセフィ (大正製薬); ルセフィ (大正製薬)
説明
Luseogliflozin hydrate, which is an SGLT2 inhibitor approved in
Japan in March 2014 for the treatment of type 2 diabetes, was discovered
by Taisho Pharmaceutical and jointly developed and marketed
with Novartis as Lusefi®. Luseogliflozin selectively binds
and inhibits human SGLT2 with a Ki of 1.10 nM and IC50 value of
2.26 nM.
ルセオグリフロジン水和物 上流と下流の製品情報
原材料
準備製品